Physician profile
Mark Yoffe
NPI 1770523227
$3,842.82
in general payments reported to CMS, 2019-2025
20 companies · $79.50 in 2025
The $79.50 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $211 · 2021: $408 · 2022: $1,765 · 2023: $409 · 2025: $79.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,765.00 | 2022 | |
| Janssen Biotech, INC. | $324.70 | 2021-2023 | Erleada, Tecvayli |
| Celgene Corporation | $185.24 | 2019 | |
| Merck Sharp & Dohme LLC | $152.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $126.26 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2019 | |
| Beigene USA, INC. | $124.73 | 2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $121.84 | 2019 | |
| Genzyme Corporation | $121.32 | 2021 | |
| Cook Medical LLC | $106.92 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.01 | 2019 | |
| Pfizer INC. | $85.84 | 2019-2020 | |
| Epizyme, INC. | $79.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.50 | 2025 | Opdivo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $77.34 | 2019 | |
| Seagen INC. | $76.95 | 2020 | |
| Puma Biotechnology, INC. | $59.68 | 2020 | |
| Incyte Corporation | $27.80 | 2023 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yoffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.